Andrea Ciamarone

Via Morego 30
Genoa, 16163, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

New allosteric modulators of molecular chaperone TRAP1 from the integration of computational biology, medicinal chemistry, and biophysics.

New allosteric modulators of molecular chaperone TRAP1 from the integration of computational biology, medicinal chemistry, and biophysics.

Journal: Cell stress & chaperones

Published: February 13, 2026

Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer.

Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 19, 2025

Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution.

Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 22, 2025

Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [68Ga]Ga-OncoACP3-DOTA.

Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [68Ga]Ga-OncoACP3-DOTA.

Journal: European urology

Published: September 11, 2025

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells.

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 24, 2025

Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity.

Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity.

Journal: Cell death discovery

Published: October 14, 2024

New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.

New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.

Journal: Journal of medicinal chemistry

Published: July 02, 2024

Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.

Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.

Journal: Nature biomedical engineering

Published: March 08, 2024

An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer.

An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer.

Journal: European journal of medicinal chemistry

Published: October 27, 2023

Novel Insights into RAD52's Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies.

Novel Insights into RAD52's Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies.

Journal: Cancers

Published: February 08, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026